Part D Catastrophic Coverage: Manufacturers Could Agree To Increased ‘Liability’
But drug makers want their financial contribution to go toward reducing beneficiary costs, not to replace plans’ insurance risk, according to comments submitted to two House committees on draft legislation.
You may also be interested in...
Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.
Biopharma manufacturers might not like the cost offsets that would cover the out-of-pocket maximum for patients in Medicare's drug program; committees seek comment on range of issues.
US HHS Office of Inspector General clears company program to provide travel expenses and lodging to needy patients located far from designated treatment centers.